74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Envista Holdings Corp
Open
SectorHealthcare
20.84 -1.09
Overview
Share price change
24h
Min
20.77
Max
21.14
Income | 8.4M 26M |
|---|---|
Sales | 65M 682M |
P/E Sector Avg | 66.188 35.733 |
EPS | 0.26 |
Profit margin | 3.87 |
Employees | 12,300 |
EBITDA | 40M 79M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +4.27% upside |
Next Earnings | 29 Oct 2025 |
|---|
Market Cap | -5.6M 3.5B |
|---|---|
Previous open | 21.93 |
Previous close | 20.84 |
News Sentiment
By Acuity
50%
50%
173 / 371 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Envista Holdings Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Envista Holdings Corp Forecast
Price Target
By TipRanks
4.27% upside
12 Months Forecast
Average 22.22 USD 4.27%
High 25 USD
Low 18 USD
Based on 11 Wall Street analysts offering 12 month price targets forEnvista Holdings Corp - Dist in the last 3 months.
Sentiment
By Acuity
173 / 371 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Envista Holdings Corp
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Live chat